Health Care [ 4/12 ] | Biotechnology [ 18/74 ]
NASDAQ | Common Stock
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA.
It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.
In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars.
Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome.
The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 11, 25 | 3.44 Increased by +4.24% | 3.36 Increased by +2.26% |
| Oct 30, 24 | 4.08 Decreased by -6.42% | 3.79 Increased by +7.65% |
| Aug 1, 24 | 5.28 Increased by +31.34% | 4.03 Increased by +31.02% |
| Apr 24, 24 | 3.67 Increased by +7.94% | 3.45 Increased by +6.38% |
| Feb 13, 24 | 3.30 Decreased by -18.52% | 3.18 Increased by +3.77% |
| Nov 8, 23 | 4.36 Decreased by -8.60% | 3.97 Increased by +9.82% |
| Jul 25, 23 | 4.02 Decreased by -23.43% | 3.77 Increased by +6.63% |
| Apr 25, 23 | 3.40 Decreased by -22.37% | 3.28 Increased by +3.66% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 2.45 B Increased by +2.87% | 266.80 M Increased by +6.85% | Increased by +10.87% Increased by +3.87% |
| Sep 30, 24 | 2.47 B Decreased by -2.55% | 388.50 M Increased by +670.48% | Increased by +15.76% Increased by +685.41% |
| Jun 30, 24 | 2.35 B Decreased by -4.19% | 583.60 M Decreased by -1.35% | Increased by +24.80% Increased by +2.97% |
| Mar 31, 24 | 2.20 B Decreased by -10.67% | 393.40 M Increased by +1.42% | Increased by +17.88% Increased by +13.53% |
| Dec 31, 23 | 2.39 B Decreased by -6.20% | 249.70 M Decreased by -54.63% | Increased by +10.46% Decreased by -51.63% |
| Sep 30, 23 | 2.53 B Increased by +0.87% | -68.10 M Decreased by -106.00% | Decreased by -2.69% Decreased by -105.95% |
| Jun 30, 23 | 2.46 B Decreased by -5.14% | 591.60 M Decreased by -44.08% | Increased by +24.09% Decreased by -41.05% |
| Mar 31, 23 | 2.46 B Decreased by -2.72% | 387.90 M Increased by +74.89% | Increased by +15.75% Increased by +79.77% |